RWB
AMRX icon

RMR Wealth Builders’s Amneal Pharmaceuticals AMRX Stock Holding History

RMR Wealth Builders’s Portfolio AMRX Stock Details AMRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-3,500
Closed -$24K – 198
2021
Q1 		$24K Buy
+3,500
New +$19.4K 0.01% 484

Other funds holding AMRX

FI
Fosun International Hong Kong, China $446M AUM 13.33% 1-Year Est. Return
TGHSA
TPG Group Holdings (SBS) Advisors Fort Worth, Texas $10.1B AUM 22.58% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
EP
Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return

RMR Wealth Builders's AMRX Position: Q2 2021 in Review

RMR Wealth Builders sold out of Amneal Pharmaceuticals (AMRX) in Q2 2021, closing a stake of 3,500 shares — an estimated $24K sold.

RMR Wealth Builders first reported a position in AMRX in Q1 2021 and held it in 1 quarter. The position peaked at $24K in Q1 2021. 160 funds tracked by Wall St. Rank hold AMRX as of Q2 2021.

  • RMR Wealth Builders reported no remaining Amneal Pharmaceuticals position as of Q2 2021 after selling out during the quarter.
  • RMR Wealth Builders sold 3,500 Amneal Pharmaceuticals shares in Q2 2021, an estimated $24K.
  • RMR Wealth Builders first reported a position in Amneal Pharmaceuticals in Q1 2021 and held it in 1 quarter.
  • RMR Wealth Builders's Amneal Pharmaceuticals position peaked at $24K in Q1 2021.
  • 160 funds tracked by Wall St. Rank held Amneal Pharmaceuticals as of Q2 2021.

Based on RMR Wealth Builders's 13F filing for Q2 2021, filed 16 Aug 2021.